Best-in-Class IL2 GNUV204 has been selected by the Korean government for a development grant
The Korea Drug Development Fund (KDDF) is contributing more than $750,000 towards the clinical development of GNUV204, a next-generation immuno-oncology therapy. GNUV204 is an Fc-fusion interleukin 2 protein, which plays a key role in the activation and proliferation of tumor-fighting T-cells. GNUV204 is intended to be used as a monotherapy or in combination with other immuno-oncology drugs.
Our latest drug candidate was created using NuvoFc™, a platform for the development of asymmetric bi-specific antibodies. The KDDF funding will help Genuv accelerate the clinical development of GNUV204.
To view original article, please click here.